# MYO5A

Source: https://onco.cc/targets/myo5a/  
OnCo record `myo5a` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MYO5A (Unconventional myosin-Va) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Hepatocellular carcinoma, Lung cancer and 1 more.

## Summary

Processive actin-based motor that can move in large steps approximating the 36-nm pseudo-repeat of the actin filament. Can hydrolyse ATP in the presence of actin, which is essential for its function as a motor protein. Involved in melanosome transport.

IntOGen calls it a driver in 4 cohorts (2 activating, 1 loss-of-function), covering Invasive Breast Carcinoma, Hepatocellular Carcinoma, Lung, Neuroblastoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: myosin VA; Unconventional myosin-Va; MYO5; GS1; MYR12; MYH12
- Tags: cancer-genes-wave
- Symbol: MYO5A
- Class: oncogene
- Biology: Processive actin-based motor that can move in large steps approximating the 36-nm pseudo-repeat of the actin filament. Can hydrolyse ATP in the presence of actin, which is essential for its function as a motor protein. Involved in melanosome transport. Also mediates the transport of vesicles to the plasma membrane. May also be required for some polarisation process involved in dendrite formation. Locus 15q21.2 (HGNC).
- Where found: Breast cancer: IntOGen driver in 1 cohort (BRCA); Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC); Lung cancer: IntOGen driver in 1 cohort (LUNG); Neuroblastoma: IntOGen driver in 1 cohort (NBL)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:7602: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7602
- UniProt Q9Y4I1: https://www.uniprot.org/uniprotkb/Q9Y4I1/entry
- NCBI Gene 4644: https://www.ncbi.nlm.nih.gov/gene/4644
- Ensembl ENSG00000197535: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197535

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)

---
JSON: https://onco.cc/api/v1/entities/myo5a.json